Breast Cancer Therapeutics in Major Developed Markets to 2021

1
Breast Cancer Therapeutics in Major Developed
Markets to 2021 - Growth Driven by Rapid Uptake
of Premium Priced Biologics and Rising Incidence
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview

• Summary
• Breast cancer, a malignant neoplasm, is the
  second most common cancer and the most common
  cancer in women worldwide, accounting for 16 of
  all female cancers, making the disease
  exceedingly prevalent. The number of women
  diagnosed with breast cancer has increased over
  the past few decades, but the number of deaths
  has declined due to earlier diagnosis and better
  treatment options.
• Breast cancer treatment has been revolutionized
  in the past four decades, especially with
  increasing usage of targeted therapies. The
  marketed products landscape comprises a wide
  range of treatment options, including hormonal
  therapies, chemotherapies, combination therapies,
  and targeted therapies. Nevertheless, significant
  unmet need remains for products that can improve
  overall survival rate, time to disease
  progression, and overall response.
• Read More At http//www.researchbeam.com/breast-c
  ancer-therapeutics-in-major-developed-to-2021-grow
  th-driven-by-rapid-uptake-of-premium-priced-biolog
  ics-and-rising-incidence-market

3


Table of Content
1 Table of Contents 41.1 List of Tables 71.2
List of Figures 7 2 Introduction 92.1 Disease
Introduction 92.2 Symptoms 103 Marketed
Products 243.1 Overview 243.2 Conclusion 39 4
Pipeline Products 404.1 Pipeline Products 404.2
Clinical Trials 445 Promising Drug Candidates
in Pipeline 545.1 Abemaciclib - Eli Lily 545.2
Buparlisib - Novartis 55
4


Table of Content
6 Market Forecast to 2021 706.1 Geographical
Markets 706.2 Global Market 707 Drivers and
Barriers for the Disease Market 827.1 Drivers
827.2 Barriers 828 Deals and Strategic
Consolidations 848.1 Licensing Deals 848.2
Co-development Deals 909 Appendix 959.1 All
Pipeline Drugs by Phase of Development 959.2
Market Forecasts to 2021 152Enquire At
http//www.researchbeam.com/breast-cancer-therapeu
tics-in-major-developed-to-2021-growth-driven-by-r
apid-uptake-of-premium-priced-biologics-and-rising
-incidence-market/enquire-about-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/breast-cancer-therapeu
tics-in-major-developed-to-2021-growth-driven-by-r
apid-uptake-of-premium-priced-biologics-and-rising
-incidence-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com